February 25, 2015
Nippon Boehringer Ingelheim and Eli Lilly Japan said on February 24 that they launched the selective sodium glucose co-transporter-2 (SGLT-2) inhibitor Jardiance Tablets 10 mg and 25 mg (empagliflozin) on the same day. Jardiance, a type 2 diabetes treatment, is...read more